CASTLEFORD, England, January 18, 2012 /PRNewswire/ --
We are pleased to announce the day-one launch of Latanoprost 0.005% w/v Eye Drops solution 2.5ml.
It is indicated in the treatment of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension.
Latanoprost is currently available as Xalatan® (Latanoprost) from Pfizer Limited. Latanoprost is now available from Teva to fulfil generic prescriptions.
Latanoprost is available immediately in the
award-winning Teva 360 livery. The strength and presentation is as follows:
Teva
Brand
Product Strength Pack Size Indication retail price price
Reduction of
elevated
intraocular
pressure in
patients with open
angle glaucoma and
Latanoprost ocular
Eye Drops 0.005% w/v 2.5ml x 1 hypertension GBP3.74 GBP12.48
Kim Innes, Commercial Director at Teva said: "As the leading generics company in the country and with the widest portfolio of our competitors, Teva continues to lead with strong product launches and patent expired products. This is our inaugural product launch for 2012 and our first day-one patent expiry of the year.
"It's good for Pharmacy, because patent expiries provide them with the opportunities for increasing margins and keeping costs down. But, even more importantly, we're providing high-quality medicines for patients whilst doing our bit to save the NHS over £9bn a year."
New or existing customers can order through their wholesaler or contact their local Teva Territory Sales Manager, or call 0800-085-8621.
To find out more about Teva UK Limited, visit http://www.tevauk.com.
*Brand price at 17 January 2012
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $16.1 billion in net sales in 2010.
For media enquiries, contact the Teva UK Limited Media team on +44-(0)1977-628500, or email media.enquiries@tevauk.com.
Share this article